CHARM offensive against heart failure;CHARM-offensief tegen hartfalen

Geneesmiddelenbulletin

Volumn 38, Issue 4, 2004, Pages 29-31

  Kerst, A J F A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; SPIRONOLACTONE;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPOTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; NOTE; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

EID: 1642270409     PISSN: 03044629     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. White HD. Candesartan and heart failure: the allure of CHARM. Lancet 2003; 362: 754-755.
2. McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking ACE inhibitors: the CHARM-added trial. Lancet 2003; 362: 767-771.
3. Granger CB, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to ACE inhibitors: the CHARM-alternative Lancet 2003; 362: 772-776.
4. Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003; 362: 777-781.
5. Pfeffer MA, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003; 362: 759-766.